Further development progress was announced this week by PharmAthene for its second generation rPA anthrax vaccine SparVax.
"SparVax is the first medical countermeasure to successfully transition from early research funded by the National Institutes of Health to advanced development in partnership with the Biomedical Advanced Research and Development Authority," Eric I. Richman, the president and CEO or PharmAthene, said. "SparVax represents how our medical countermeasure development program can create products with desired characteristics to meet the needs of our country. We look forward to continuing a very productive collaboration with our partners in government to address this need and advance this important product."
The company recently completed its first cGMP manufacturing run at 1,5000 liter commercial scale for the vaccine, which is being developed as a means of providing rapid manufacturing scale-up to respond to a national security emergency.
Final analytics testing is ongoing and expected to be completed in December.
"There is widespread acknowledgement of the need for a modern, next-generation anthrax vaccine that can meet the government's needs in the event of an emergency," Richman said. "A recombinant anthrax vaccine offers the potential for an improved vaccine that is safe, convenient, cost-effective and provides for a significant increase in production yields."